Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation

Movement Disorders

Volumn 21, Issue 11, 2006, Pages 1941-1946

  Ardouin, Claire ^a   Voon, Valerie ^b   Worbe, Yulia ^c   Abouazar, Nehman ^a   Czernecki, Virginie ^c   Hosseini, Hassan ^d   Pelissolo, Antoine ^c   Moro, Elena ^b   Lhommée, Eugénie ^a   Lang, Anthony E ^b   Agid, Yves ^c   Benabid, Alim Louis ^e   Pollak, Pierre ^a   Mallet, Luc ^c   Krack, Paul ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Deep brain stimulation; Dopamine; Parkinson's disease; Pathological gambling; Subthalamic nucleus

Indexed keywords

BROMOCRIPTINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; ROPINIROLE;

ADULT; APATHY; ARTICLE; BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; DESENSITIZATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; HUMAN; MALE; MONOTHERAPY; MOOD; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS; SYMPTOM;

ADULT; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRIC STIMULATION THERAPY; FEMALE; FOLLOW-UP STUDIES; GAMBLING; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBTHALAMIC NUCLEUS;

EID: 33845209627     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21098     Document Type: Article

References (44)

1. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67: 492-496.
2. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
3. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
4. Molina JA, Sainz-Artiga MJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-Pareja M, Bermejo-P F. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment. Mov Disord 2000;15:869-872.
5. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423.
6. Dodd ML, Klos KJ, Bower J, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat parkinson disease. Arch Neurol 2005;62:1377-1381.
7. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-529.
8. Potenza MN, Kosten TR, Rounsaville BJ. Pathological gambling. JAMA 2001;286:141-144.
9. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
10. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-707.
11. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005;76:1640-1644.
12. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano A, Lang AE. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2004;99:489-495.
13. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-163.
14. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
15. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17:393-398.
16. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.
17. Beck AT, Ward CH, Mendelson M, Mack J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571.
18. Schmidt R, Freidl W, Fazekas F, et al. The Mattis dementia rating scale: normative data from 1,001 healthy volunteers. Neurology 1994;44:964-966.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
20. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005;20:1052-1055.
21. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8:147-148.
22. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-dopa medication remediates cognitive inflexibility, but increases impuslivity in patients with Parkinson's disease. Neuropsychologia 2003;41:1431-1441.
23. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998;80:1-27.
24. Fiorillo C, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003; 299:1898-1902.
25. Potenza MN, Stienberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003;60:828-836.
26. Cavedini P, Riboldi G, Keller R, D'Annunci A, Bellodi L. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry 2002;51:334-341.
27. Bechara A. Neurobiology of decision-making: risk and reward. Sem Clin Neuropsychiatry 2001;6:205-216.
28. Bechara A, Tranel D, Damasio H. Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 2000;123:2189-2202.
29. Brown RG, Pluck G. Negative symptoms: the "pathology" of motivation and goal-directed behaviour. Trends Neurosci 2000;23: 412-417.
30. Fahn S, Oakes D, Shoulson I, et al., Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2547-2549.
31. Funkiewiez A, Ardouin C, Caputo E, et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:834-839.
32. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;10(Suppl.):S109-S115.
33. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
34. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 1997;350:1676.
35. Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea: the clinical spectrum of varying subthalamic nucleus activity. Brain 1999; 122: 1133-1146.
36. Muriel MP, Agid Y, Hirsch E. Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease. Mov Disord 2001;16:435-441.
37. Bejjani BP, Arnulf I, Demeter S, Damier P, Bonnet AM, Houeto JL, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol 2000;47:655-658.
38. Krack P, Ardouin C, Funkiewiez A, Caputo E, Benazzouz A, Benabid AL, Pollak P. What is the influence of STN stimulation on the limbic loop? In: Kultas-Ilinsky K, Ilinsky IA, editors. Basal Ganglia and Thalamus in Health and Movement Disorders. New York: Kluwer Academic/Plenum Publishers; 2001. p 333-340.
39. Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006 April 10 Epub ahead of print.
40. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524-530.
41. Czernecki V, Pillon B, Houcto JL, Welter ML, Mesnage V, Agid Y, Dubois B. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry 2005;76:775-779.
42. Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson's disease. Arch Gen Psychiatry 2003;60:296-302.
43. Darbaky Y, Baunez C, Arecchi P, Legallet E, Apicella P. Reward-related neuronal activity in the subthalamic nucleus of the monkey. Neuroreport 2005;16:1241-1244.
44. Baunez C, Amalric M, Robbins TW. Enhanced food-related motivation after bilateral lsions of the subthalamic nucleus. J Neurosci 2002;22:562-568.